Therabron Therapeutics’s Chief Scientist, Dr. Aprile Pilon, was invited to present a poster and to give a short presentation at a workshop entitled, “Mechanisms of Lung Injury and Immunomodulator Interventions […]
- Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.
- Therabron Therapeutics to Present at Stifel 2016 Healthcare Conference
- Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
- Therabron Therapeutics to Present at Upcoming Industry and Investor Conferences
- Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants